# EuGeni Rapid Antigen Test for the Qualitative Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Causing COVID19 Disease in Compliance With the World Health Organization (WHO)

> **NCT05618561** · — · TERMINATED · sponsor: **AnteoTech Ltd** · enrollment: 599 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **DIAGNOSTIC_TEST:** EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test

## Key facts

- **NCT ID:** NCT05618561
- **Lead sponsor:** AnteoTech Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-26
- **Primary completion:** 2022-08-25
- **Final completion:** 2022-11-02
- **Target enrollment:** 599 (ACTUAL)
- **Why stopped:** High number of false negatives
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05618561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05618561, "EuGeni Rapid Antigen Test for the Qualitative Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Causing COVID19 Disease in Compliance With the World Health Organization (WHO)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05618561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*